medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2018, Number 4

<< Back Next >>

Rev Invest Clin 2018; 70 (4)

Roles of Donor/Recipient Body Surface Area Ratio and Donor Kidney Glomerular Filtration Rate in Kidney Selection for Living Transplantation from Family Members

Zheng Y, Guan Y, Li Z, Zhang G, Guo Y, Ai X

Language: English
References: 16
Page: 169-176
PDF size: 94.11 Kb.


ABSTRACT

Background: Accurate assessing donor renal function is crucial to the success of living kidney transplants. We studied the roles of donor kidney glomerular filtration rate (GFR) and donor/recipient body surface area (BSA) ratio in kidney selection for living transplantation from family members. Methods: We included 204 recipients who were subjected to living kidney transplantation from family members in our hospital from February 2011 to February 2015 and followed up for over 2 years. Recipients were divided into six groups according to donor GFR and donor/recipient BSA ratio. The effects of donor GFR or donor/recipient BSA ratio on the recovery of renal graft functions were evaluated. Results: The post-operative serum creatinine (SCr) reduction rate, steady-state SCr level, and estimated GFR (eGFR) of the group with donor GFR ≥ 40 ml/min were slightly higher to those of the group with donor GFR ‹ 40 ml/min (p › 0.05). The renal function recovery of the group with donor/ recipient BSA ratio ≤ 0.8 was significantly lower than that of the group with donor/recipient BSA ratio ≥ 1.2 (p ‹ 0.05). The post-operative SCr reduction rate, steady-state SCr level, and eGFR of the group with GFR ‹ 40 ml/min and donor/recipient BSA ratio ≤ 0.8 were all significantly lower than those of the other five groups (P ‹ 0.05). Such values of the two groups with donor/recipient BSA ratio ›1.2 were significantly higher than those of the other four groups (p ‹ 0.05). Conclusions: The selection of donor kidneys from relatives for living kidney transplantation should also consider donor/recipient BSA ratio in addition to donor GFR.


REFERENCES

  1. Haynes R, Harden P, Judge P, et al. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet. 2014;384:1684-90.

  2. Stegall MD, Gaston RS, Cosio FG, Matas A. Through a glass darkly: seeking clarity in preventing late kidney transplant failure. J Am Soc Nephrol. 2015;26:20-9.

  3. Levine DJ, Glanville AR, Aboyoun C, et al. Antibody-mediated rejection of the lung: a consensus report of the international society for heart and lung transplantation. J Heart Lung. 2016;35:397-406.

  4. Venner JM, Hidalgo LG, Famulski KS, Chang J, Halloran PF. The molecular landscape of antibody-mediated kidney transplant rejection: evidence for NK involvement through CD16a Fc receptors. Am J Transplant. 2015;15:1336-48.

  5. Hutchinson JA, Geissler EK. Now or never? The case for cellbased immunosuppression in kidney transplantation Kidney Int. 2015;87:1116-24.

  6. Haarberg KM, Tambur AR. Detection of donor-specific antibodies in kidney transplantation. Br Med Bull. 2014;110:23-34.

  7. Loupy A, Haas M, Solez K, et al. The banff 2015 kidney meeting report: current challenges in rejection classification and prospects for adopting molecular pathology. Am J Transplant. 2017; 17:28-41.

  8. Halloran PF, Famulski K, Reeve J. The molecular phenotypes of rejection in kidney transplant biopsies. Curr Opin Organ Transplant. 2015;20:359-67.

  9. Shojaei H, Hashemi A, Heidarieh P, Hosseini N, Daei Naser A. Chronic pulmonary disease due to Mycobacterium monacense infection: the first case from Iran. Ann Lab Med. 2012;32:87-90.

  10. Kulkarni S, Kirkiles-Smith NC, Deng YH, et al. Eculizumab therapy for chronic antibody-mediated injury in kidney transplant recipients: a pilot randomized controlled trial. Am J Transplant. 2017;17:682-91.

  11. Anglicheau D, Naesens M, Essig M, Gwinner W, Marquet P. Establishing biomarkers in transplant medicine: a critical review of current approaches. Transplantation. 2016;100:2024-38.

  12. Higgins RM, Daga S, Mitchell DA. Antibody-incompatible kidney transplantation in 2015 and beyond. Nephrol Dial Transplant. 2014;30:1972-8.

  13. Legris T, Picard C, Todorova D, et al. Antibody-dependent NK cell activation is associated with late kidney allograft dysfunction and the complement-independent alloreactive potential of donor-specific antibodies. Front Immunol. 2016;7:288.

  14. O’Connor EM, Koufaki P, Mercer TH, et al. Long-term pulse wave velocity outcomes with aerobic and resistance training in kidney transplant recipients-A pilot randomised controlled trial. PLoS One. 2017;12:e0171063.

  15. Baron PW, Infante S, Peters R, et al. Post-transplant diabetes mellitus after kidney transplant in Hispanics and caucasians treated with tacrolimus-based immunosuppression. Ann Transplant. 2017;22:309-14.

  16. Wainright JL, Klassen DK, Kucheryavaya AY, Stewart DE. Delays in prior living kidney donors receiving priority on the transplant waiting list. Clin J Am Soc Nephrol. 2016;11:2047-52.




2020     |     www.medigraphic.com